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Abstract
Background: The FTO gene has recently become one of the most extensively investigated genes associated with
body mass and has been shown to play a role in cardiovascular diseases as well. The aim of the current study was
to investigate the effect of a common variant of FTO gene, rs9939609 in obese and coronary heart disease (CHD)
patients of Pakistan and investigate whether it has any influence on the serum biochemical parameters.
Methods: A total of 970 samples (295 obese, 425 CHD and 250 controls) were genotyped using TaqMan allelic
discrimination assay. Serum total cholesterol, HDL-C and triglycerides were measured using spectrophotometric
methods. LDL-C was calculated by Friedwalds equation. Statistical analysis was done by SPSS version 22.
Results: Results showed moderately high minor allele frequency (MAF) in obese and CHD cases as compared to
controls (obese = 0.381 CAD = 0.361 and controls = 0.286). The variant was significantly associated with obesity and
CAD (obesity odds ratio (OR) = 1.54, confidence interval (CI) = 1.07–2.21, p = 0.0009; CHD OR = 1.43, CI = 1.02–2.01,
p = 0.004) in Pakistan. The risk allele did not show a significant association with any of the lipid trait tested (p > 0.05)
but a strong association was observed with plasma glucose levels (obese p = 0.001, CAD p = 0.014, controls p = 0.019).
Conclusion: In conclusion, the variant was associated with obesity and CAD in the studied subjects and its possible
effect may involve the blood sugar metabolism but not serum lipid chemistry.
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Background
Obesity, defined as excessive accumulation of body fat,
is a complex disorder whose pathogenesis involves both
environmental and genetic factors. Obesity, a complex
disorder, is a strong predisposing risk factor for several
other diseases, like diabetes, hypertension and CAD [1].
In Pakistan a dramatic increase in the prevalence of
obesity has been observed recently and currently 5.2 %
females and 1.6 % males in Pakistan over the age of 15
are obese [2]. As the preventive and therapeutic mea-
sures employed so far have failed to bring about the ex-
pected results, new pathogenic mechanisms of the
disease are being looked for. However, only a small pro-
portion of body mass index (BMI) could be explained on
genetic bases due to small effect size of the variants
studied [3]. While some forms of obesity are caused by
single mutations, most cases are polygenic and result
from a complex interaction between the genotype and
the environment [4].
Coronary heart disease (CAD) is the leading cause of
death worldwide. Despite being manageable, the mortal-
ity rate is increasing in developing countries and the dis-
ease burden is likely to be doubled by 2020 in these
countries [5]. Asian population is more susceptible to
heart diseases and a 50 % higher prevalence of cardio-
vascular diseases has been reported in South Asians [6].
Pakistan which is a country of >180 million people has
high burden of CAD like rest of the world [7]. The
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prevalence of CAD risk factors is high in Pakistani popu-
lation and more than 30 % of the people above 45 years
of age are affected by the disease [8]
CAD being a complex interplay between environmen-
tal, life style and genetic factors, a large number of genes
have been investigated for having their role in the devel-
opment of the disease. As CAD can be a sequel of obes-
ity, the genes involved in the development of obesity
have also been investigated of having any role in the de-
velopment of CAD [9].
The FTO gene has recently become one of the most ex-
tensively investigated genes associated with body mass
[10]. It spans more than 400Kb on chromosome 16 and
has nine exons [11]. Despite large size of FTO gene, vari-
ants implicated in obesity and weight gain are largely
located in the first intron [12]. FTO protein is a 2-
oxyglutarate dependent non-heme dioxygenase family
member and localizes in nucleus [13]. Previously FTO was
thought to be highly expressed in the hypothalamic nuclei
involved in energy balance but recent rodent studies sug-
gest that in addition to hypothalamus, it is also expressed
in the peripheral tissues like pancreas [14]. The associ-
ation of FTO variant, rs9939609 with obesity has been
confirmed in Caucasians, and the results in Asian popula-
tions were initially somewhat conflicting [15–21], how-
ever, substantial data on association of this variant with
BMI and obesity is now available in Chinese, Japanese,
Korean and Filipino populations [22–25]. A meta-analyses
of published studies in Asians reported that the minor al-
lele for the rs9939609 significantly (p = 9 × 10−9) increased
the risk of obesity [10]. Fewer studies in South Asians have
been reported, two of which confirmed the association be-
tween the FTO locus and obesity susceptibility [26, 27],
whereas one study did not [28].
The association of FTO gene variant rs9939609 with
CAD has been reported by many studies [29–31].
Though not fully understood, the underlying mechanism
of progression to ischemic heart disease involves an
array of events like insulin resistance, endothelial dam-
age and inflammation [32]. Since obesity, metabolic
syndrome and CAD are interrelated through a complex
interaction of genetic and environmental factors [33],
the SNP has also been reported to be associated with
cardiovascular disease [34]. Keeping in view the import-
ance of this variant in energy metabolism and contra-
dictory results reported so far, we aimed to investigate
the association of the FTO rs9939609 T > A single-
nucleotide polymorphism (SNP) in Pakistani obese,
CAD patients and control subjects and observe the ef-
fect of this variant on selected biochemical parameters.
Results
The baseline characteristics of the study subjects are
given in Table 1. A higher proportion of males were hav-
ing CAD and obesity than females, but the difference
was not significant. The CAD cases belonged to an elder
age group as compared to controls (p = 0.002) whereas
the age difference was not significant in obese cases and
controls. The lipid profile parameters including TC,
LDL-C and TG as well as blood sugar levels were signifi-
cantly higher in obese and CAD cases as compared to
controls. Whereas HDL-C was lower in both cases than
control subjects. The genotype call rate was 97 % for
obese, 98 % for CAD and 98 % for the control group.
The mean weight, BMI and WHR for obese subjects
were 96.16 ± 15.95, 36.92 ± 6.46 and 1.00 ± 0.09 respect-
ively, for CHD subjects were 67.13 ± 11.95, 22.46 ± 6.75
and 0.81 ± 0.06 respectively and for control subjects
67.13 ± 9.56, 21.46 ± 9.11 and 0.85 ± 0.10 respectively.
Overall, the study population was in Hardy-Weinberg
equilibrium (p = 0.938).
Association of FTO rs9939609 polymorphism with obesity
and CAD
The allele and genotype frequencies of the rs9939609 vari-
ant are shown in Table 2. The minor allele frequency
(MAFs) in CAD group was significantly higher than con-
trols (0.361 vs 0.286. Similarly, the MAF was higher in
obese cases than controls (0.381 vs 0.286). Genotype distri-
bution revealed significant differences between the cases
Table 1 Baseline features of subjects under study
Characteristic CAD Obesity
Cases (n = 425) Controls (n = 250) p-value Cases (n = 295) Controls (n = 250) p-value
Gender (M/F %) 59/41 54.3/45.7 0.271 56.2/43.8 54.3/45.7 0.873
Age (years) 59 ± 12 56 ± 10 0.002 55.32 ± 15.18 56.01 ± 10.44 0.31
TC (mmol/L) 5.36 ± 1.38 4.51 ± 1.11 9.1 × 10-14 5.54 ± 1.11 4.51 ± 1.11 2.0 × 10-24
TG (mmol/L) 2.43 ± 0.83 2.12 ± 0.74 3.6 × 10-8 2.39 ± 0.79 2.12 ± 0.74 3.1 × 10-5
HDL-C (mmol/L) 1.11 ± 0.11 1.74 ± 0.42 5.9 × 10-7 1.16 ± 0.31 1.74 ± 0.42 1.9 × 10-66
LDLD-C (mmol/L) 2.74 ± 0.74 2.18 ± 0.43 2.4 × 10-5 2.99 ± 0.56 2.18 ± 0.43 1.4 × 10-21
FBG (mg/dL) 98.42 ± 6.61 89.56 ± 7.29 1.0 × 10-46 102.71 ± 14.12 89.56 ± 7.29 2.4 × 10-31
The table summarizes the general characteristics of the study subjects by comparing the cases with controls. CAD Coronary heart Disease group, TC Total
Cholesterol, TG Triglycerides, HDL-C High Density Lipoprotein cholesterol, LDL-C Low Density Lipoprotein cholesterol, FBG fasting blood glucose
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and controls (CAD: TT = 44 %, TA= 39.76 %, AA =
16.24 %; obese: TT= 39.32 %, TA= 45.08 %, AA= 15.59 %
vs controls TT = 45.2 %, TA = 36.4 %, AA = 18.4 %). Over-
all, the frequency of TT genotype was 42.88 %, of TA was
40.51 % and of AA was 16.59 %. The FTO rs9939609 poly-
morphism was found to be significantly associated with
obesity as well as CAD in Pakistani subjects. The per allele
odds ratio (OR) for CAD was 1.43 (1.02–2.01) which is a
significant association (p = 0.004). Similarly the association
with obesity was found to be significant (p = 0.0009) with
an OR of 1.54 (1.07–2.21).
Effect of FTO rs9939609 polymorphism on biochemical
parameters
ANOVA was used to check whether the selected variant
had any influence on serum biochemical traits (Table 3).
The SNP did not appear to affect any of the tested lipid
traits to a significant extent. A careful examination of
the results revealed that the presence of the risk allele in
homozygous state increased triglyceride level slightly
when compared to TT or TA genotype in obese subjects
and controls, whereas there is a decrease in HDL-C
levels in all groups when the AA genotype is compared
to TT or TA genotype although the effect is not statisti-
cally significant. However, the SNP appeared to be un-
ambiguously associated with fasting blood sugar
concentrations in CAD (p = 0. 014), obese (p = 0.001)
and control (p = 0.019) groups.
Discussion
We have studied the association of FTO polymorphism
rs9939609 with obesity and CAD in Pakistani popula-
tion. Some FTO variants already associated with obesity
are also associated with CAD risk factors (17). We pro-
posed that since obesity is a well established risk factor
for CAD, it is likely that the FTO gene, as the BMI/
Table 2 Allele/genotype frequencies of rs9939609 in study group
Genotype/
allele
Frequency OR (CI), p-value
Obese (n = 295) CAD (n = 425) Control (n = 250) Obesity CAD
TT 116 187 133 1.54 (1.07–2.21), 0.0009* 1.43 (1.02–2.05), 0.004*
TA 133 169 91
AA 46 69 26
T 0.621 0.637 0.716
A 0.379 0.363 0.284
The table shows the association of allele/genotype frequencies of rs9939609 in the cases and the control group. CAD Coronary Artery Disease group, OR Odds
Ratio, CI Confidence Interval. *indicates any significant association
Table 3 Effect of rs9939609 on biochemical traits in the study subjects
Group Parameter Genotype p-value
TT TA AA
Controls (n = 250) Total cholesterol (mmol/L) 4.38 ± 1.12 4.72 ± 1.36 4.67 ± 0.66 0.123
Triglycerides (mmol/L) 2.34 ± 0.66 2.16 ± 0.75 2.73 ± 1.22 0.109
HDLC (mmol/L) 1.80 ± 0.41 1.67 ± 0.15 1.65 ± 0.43 0.119
LDLC (mmol/L) 2.13 ± 0.41 2.25 ± 0.48 2.26 ± 0.55 0.187
FBG (mg/dL) 90.54 ± 6.81 90.81 ± 7.98 89.81 ± 5.41 0.019*
CAD (n = 425) Total cholesterol (mmol/L) 5.41 ± 1.41 5.30 ± 1.36 5.38 ± 1.37 0.735
Triglycerides (mmol/L) 2.35 ± 0.85 2.43 ± 0.81 2.41 ± 0.66 0.603
HDLC (mmol/L) 1.15 ± 0.32 1.18 ± 0.29 1.16 ± 0.30 0.795
LDLC (mmol/L) 2.73 ± 0.72 2.75 ± 0.73 2.71 ± 0.85 0.953
FBG (mg/dL) 97.14 ± 6.81 98. + 1 ± 5.98 100.41 ± 6.41 0.014*
Obese (n = 295) Total cholesterol (mmol/L) 5.50 ± 0.91 5.50 ± 0.74 5.49 ± 0.64 0.998
Triglycerides (mmol/L) 2.51 ± 0.76 2.46 ± 0.75 2.71 ± 1.05 0.405
HDLC (mmol/L) 1.11 ± 0.11 1.13 ± 0.11 1.07 ± 0.10 0.105
LDLC (mmol/L) 2.96 ± 0.56 3.04 ± 0.54 2.95 ± 0.58 0.552
FBG (mg/dL) 101.91 ± 13.52 104.21 ± 17.65 109.92 ± 16.54 0.001*
The table shows a comparison of mean biochemical parameters for three different genotypes in the study groups with strength of effect indicated by the p-value.
CAD Coronary Artery Heart group, HDL-C High Density Lipoprotein cholesterol, LDL-C Low Density Lipoprotein cholesterol, FBG fasting blood glucose,*indicates
any significant association
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obesity related locus, might confer the risk of CAD. The
SNP was found to be significantly associated with both
obesity and CAD.
We found the frequency of risk allele (A) was higher
in obese cases than controls. The risk allele of rs9939609
was significantly associated with the disease in Pakistani
population. It has been reported that the presence of
two alleles at the rs9939609 site of the FTO gene in-
creased BMI by about 1 kg/m2, body mass by 2.3Kg and
1.3-fold higher risk of overweight and obesity in both
adults and children. It has been estimated that per unit
increase in BMI increase cardiovascular disease morbid-
ity by 8 % [35]. We found similar results regarding asso-
ciation of the risk allele of rs9939609 with CAD in
Pakistani subjects. It is the first study on this variant’s ef-
fect on CAD in Pakistan and successfully replicated the
previous reports. However, the MAF was lower than re-
ported in Caucasians consistent with a previous finding
that the prevalence of the risk allele in East Asians
(~20 %) and South Asians (~30 %) is substantially lower
than in Europeans, and the reported effect sizes in both
East and South Asians vary widely for BMI (OR 0.13–
0.83 Kg/m2 per minor allele) and obesity risk (OR 1.02–
1.48 per minor allele) [36]. Regarding the association
between FTO gene and CAD risk, Doney et al first dem-
onstrated that the A allele of rs9939609 increased the
risk of myocardial infarction (MI) in 4897 patients with
type 2 diabetes (T2D) in a prospective study, which was
independent of BMI, glycohemoglobin, mean arterial
pressure, HDL-C, triglycerides, and total cholesterol
[34]. However, the subsequent studies revealed conflict-
ing conclusions [31, 37–40]. A meta-analysis conducted
in the end of 2013, comprising 19,153 cardiovascular
disease (CVD) cases and 103,720 controls, pooled all
these studies together, and found a significant associ-
ation between the FTO gene variant rs9939609 and
CVD risk independent of BMI and other conventional
CVD risk factors [41].
The variant did not appear to influence any lipid par-
ameter in the subjects tested, however, showed a consist-
ent association with blood glucose levels. Therefore, it
might play a role in progression to CAD through affect-
ing plasma glucose metabolism. This is in accordance
with a recent meta-analysis which reported that this
variant has no correlation with serum lipid chemistry,
and is associated with glucose levels [22]. However, the
mechanism underlying the association of the FTO vari-
ant with CAD risk remains unclear yet. Previously, the
rs9939609 variant was found to influence energy-dense
food intake instead of regulation of energy expenditure
[42]. In addition, it was also shown to be associated with
diabetes-related metabolic traits (including higher fasting
insulin, glucose and triglycerides, and lower HDL chol-
esterol), although the association disappeared after
adjustment for BMI [43]. Other studies have indicated
that FTO variant is associated with increased risk for
hypertension through the regulation of sympathetic ner-
vous system [44]. Notably, Hubacek et al believed that
the FTO variant could increase the risk of CAD through
another mechanism, mainly through its possible effect
on DNA methylation. In other words, the FTO gene
variant could interact with an unhealthy lifestyle (such
as high fat diet and lack of physical activity), and affect
the epigenetic status and ultimately contribute to the de-
velopment of CVD [30].
The limitations of the study included a relatively small
sample size and inability to include more biochemical
and anthropometric measures in order to observe the
real behaviour of the variant in the Pakistani ethnic
group. The findings of the study should be therefore
replicated in larger cohorts in future with more bio-
chemical parameter included in order to validate the re-
sults observed in the current investigation and find out
new associations, if any, of the variant.
In conclusion, we have shown that the FTO variant
rs9939609 is associated with obesity and showed for the
first time in Pakistan, with coronary artery disease. We
confirmed the association of this variant with plasma




A total of 970 subjects were included in the study after
obtaining informed consent. The study groups consisted
of 295 obese individuals (43.8 % females, 56.2 % males,
mean age 39.21 ± 15.18), 425 CAD patients (41 % fe-
males, 59 % males, mean age 59 ± 12) and 250 controls
(45.7 % females, 54.3 % males, mean age 56 ± 10). The
obese subjects were recruited based on BMI and waist
to hip ratio (WHR). The BMI cutoffs used were those
defined for the Asian population and have been de-
scribed elsewhere [45]. An additional measure to differ-
entiate between obese and non obese used was WHR
and a value of ≥ 0.85 in females and ≥ 1 in males was
used as cutoff [46]. The CAD patients were selected
from tertiary care hospitals of the province of Punjab,
Pakistan. These were diagnosed cases based upon the
ECG, cardiac echo, radiologic and troponine T/I levels.
These cases were recently diagnosed of having CAD and
were not taking any lipid lowering or antihypertensive
drug. Control subjects were apparently healthy individ-
uals from the general population with BMI 18.5–22.99
Kg/m2 and no history of heart disease. The exclusion
criteria included the presence of any chronic ailment like
chronic liver or kidney disease, cancers or any ongoing
acute infection or disease and CAD patients with
obesity.
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Ethics, consent and permissions
All the procedures were in compliance with the Helsinki
Declaration and the study was approved by the institu-
tional ethics committee.
Blood sample collection
Early morning blood samples were collected from the
median cubital vein taking aseptic measures. The blood
samples were collected into two vacutainers (BD, USA),
one coated with EDTA as an anticoagulant and the other
containing a gel and clot activator at the bottom. The
whole blood sample from EDTA tube was used for DNA
extraction, while the clotted blood in gel vials was cen-
trifuged at 5,000rpm for 5min to separate serum. The
serum samples were used for determining biochemical
parameters.
Determination of biochemical parameters
The serum samples were analyzed for total cholesterol
(TC), high density lipoprotein cholesterol (HDL-C) and
triglycerides (TG) levels. The end point spectrophoto-
metric methods were adopted according to the manufac-
turers’ guidelines using commercially available kits
(Human Diagnostics, Germany). LDL-C was measured
by Friedwalds equation. Epoch, Biotek microplate reader
(Biotek instruments, Highland Park) was used for all op-
tical density measurements. Fasting blood glucose (FBG)
was measured using a digital glucometer (Sky-ERA, TD
4103).
Genotyping
Genomic DNA was isolated from peripheral blood leuko-
cytes using Promega Wizard® Genomic DNA purification
kit. DNA was quantified using nanodrop (ND-8000, USA).
The DNA samples were diluted to a standard concentra-
tion of 1.25ng/μl. A 4μl of this dilution was taken to get the
final working concentration of 5ng of DNA. A liquid hand-
ling robotic system (Biomerk FX, Beckman Coulter) was
used to spot DNA in 384-well plates (Micro Amp), specially
designed for PCR amplification. Genotyping was done by
TaqMan allelic discrimination assay using primers and
probes given in Additional file 1: Table S1. The real time
PCR reaction mixture consisted of 1X KAPA probe fast
qPCR master mix (KAPABiosystems, USA), 100nM of each
primer, 100nM of each probe, ROX high (0.4μl/20 μl reac-
tion mixture), 5ng DNA and PCR grade water as needed.
The PCR program consisted of an initial temperature of
50 °C for 2 min Then denaturation/enzyme activation at
95 °C for 10 min, finally amplification for 40 cycles each
consisting of denaturation at 95 °C for 15s and amplifica-
tion at 60 °C for1 min. PCR was done on the Bird
C1000TM thermal cycler. After amplification the results
were analyzed on the ABI Prism 7900HT (Applied
Biosystems/Life Technologies) and the genotypes were
called using sequence detection software (SDS) version 2.0.
Statistical analysis
Statistical Analysis was done using Statistical Package
for Social Sciences (SPSS, IBM statistics, version 22).
Independent sample t-test was used to compare the an-
thropometric and biochemical parameters of obese and
CHD groups with the controls. The study population
was tested for Hardy Weinberg equilibrium and allele/
genotype frequencies were calculated. The significance
of difference in allele and genotype frequencies was
calculated using a chi-squared test. The odds ratio was
calculated using binary logistic regression. One-way ana-
lysis of variance (ANOVA) was used to check the effect
of rs9939609 polymorphism on biochemical parameters.
A p-value <0.05 was considered statistically significant
for all analyses.
Additional file
Additional file 1: Table S1. Primers and Probes for TaqMan Assay.
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